

RESEARCH ARTICLE

Impact of Routine Cerebral CT Angiography on Treatment Decisions in Infective Endocarditis

Marwa Sayed Meshaal^{1*}, Hussein Heshmat Kassem¹, Ahmad Samir¹, Ayman Zakaria², Yasser Baghdady¹, Hussein Hassan Rizk¹

1 Department of Cardiovascular Medicine, Cairo University, Cairo, Egypt, **2** Department of Radiology, Cairo University, Cairo, Egypt

* marwamashaal@kasralainy.edu.eg

Abstract



OPEN ACCESS

Citation: Meshaal MS, Kassem HH, Samir A, Zakaria A, Baghdady Y, Rizk HH (2015) Impact of Routine Cerebral CT Angiography on Treatment Decisions in Infective Endocarditis. PLoS ONE 10(3): e0118616. doi:10.1371/journal.pone.0118616

Academic Editor: Jeroen Hendrikse, University Medical Center (UMC) Utrecht, NETHERLANDS

Received: April 5, 2014

Accepted: January 21, 2015

Published: March 30, 2015

Copyright: © 2015 Meshaal et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by Kasr Al Ainy School of Medicine. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

Background

Infective endocarditis (IE) is commonly complicated by cerebral embolization and hemorrhage secondary to intracranial mycotic aneurysms (ICMAs). These complications are associated with poor outcome and may require diagnostic and therapeutic plans to be modified. However, routine screening by brain CT and CT angiography (CTA) is not standard practice. We aimed to study the impact of routine cerebral CTA on treatment decisions for patients with IE.

Methods

From July 2007 to December 2012, we prospectively recruited 81 consecutive patients with definite left-sided IE according to modified Duke's criteria. All patients had routine brain CTA conducted within one week of admission. All patients with ICMA underwent four-vessel conventional angiography. Invasive treatment was performed for ruptured aneurysms, aneurysms ≥ 5 mm, and persistent aneurysms despite appropriate therapy. Surgical clipping was performed for leaking aneurysms if not amenable to intervention. Results: The mean age was 30.43 ± 8.8 years and 60.5% were males. *Staph aureus* was the most common organism (32.3%). Among the patients, 37% had underlying rheumatic heart disease, 26% had prosthetic valves, 23.5% developed IE on top of a structurally normal heart and 8.6% had underlying congenital heart disease. Brain CT/CTA revealed that 51 patients had evidence of cerebral embolization, of them 17 were clinically silent. Twenty-six patients (32%) had ICMA, of whom 15 were clinically silent. Among the patients with ICMA, 11 underwent endovascular treatment and 2 underwent neurovascular surgery. The brain CTA findings prompted different treatment choices in 21 patients (25.6%). The choices were aneurysm treatment before cardiac surgery rather than at follow-up, valve replacement by biological valve instead of mechanical valve, and withholding anticoagulation in patients with prosthetic valve endocarditis for fear of aneurysm rupture.

Conclusions

Routine brain CT/CTA resulted in changes in the treatment plan in a significant proportion of patients with IE, even those without clinically evident neurological disease. Routine brain CT/CTA may be indicated in all hospitalized patients with IE.

Introduction

Despite the advances in diagnostic and therapeutic techniques, infective endocarditis (IE) remains a challenging disease with high rates of morbidity. Infective endocarditis is fatal if untreated.^[1] Clinically manifest neurological complications occur in 20%–40% of IE patients and are mostly due to brain embolization and the formation of intracranial mycotic aneurysms (ICMAs). Additionally, neurological complications in IE are strong predictors of mortality^[2,3]; the overall mortality among IE patients with ICMAs is 60% and may reach 80% with ruptured ICMAs^[4,5]. Autopsy and clinical studies have shown that a significant proportion of cerebral embolizations are clinically silent.^[6] Most ICMAs remain silent and rupture suddenly with catastrophic consequences even after apparent bacteriological cure.^[7,8] Subclinical infarcts, cerebral hemorrhage and ICMA can complicate the course of treatment and alter treatment decisions, particularly in patients who require cardiac surgery and valve replacement. Despite their high incidence and the dismal prognosis, routine screening for neurological complications is not standard practice in IE. We aimed to assess how routine performance of cerebral angiography would change the treatment decisions in a cohort of IE patients in tertiary care.

Patients and Methods

The research ethical committee of Kasr Al Ainy approved the research. The local research ethical committee approved the research protocol. We obtained verbal consent from all patients to accept participation in the study. All patients signed a written informed consent before doing CTA, four-vessel cerebral angiography or intervention and before neurosurgery, as this is routine hospital practice. We documented in the patients' files the elements of the consent form that were presented to the study participants. The consent process was witnessed in all patients by one of the patient's relative and by a registered nurse. The ethical committee approved the consent forms and consent process.

From July 2007 to December 2012 we prospectively recruited all patients with definite left-sided IE according to modified Duke's criteria.^[9] A neurologist evaluated all patients on admission. The patients were classified as having clinical evidence of brain embolization if they had either new onset of a persistent focal neurological deficit or a transient ischemic attack (TIA) defined as brief episodes of neurological dysfunction resulting from focal cerebral ischemia not associated with permanent cerebral infarction.^[10]

Trans-thoracic echocardiography (TTE) was performed using the S5-1 probe of a GE Vivid S5 echocardiography system (GE-Vingmed Ultrasound, Horten, Norway) within 24 hours of admission. Trans-esophageal echocardiography (TEE) was performed using the S7-2 probe of the same machine, if indicated, within 48 hours. All views were standardized according to the guidelines of the American Society of Echocardiography. TTE and TEE data were collected including: valve type; morphology; severity of stenosis or regurgitation; vegetation number, size,

shape, mobility and site; ventricular dimensions and systolic function as well as the presence of ring abscesses or intracardiac fistulae.

All patients underwent cerebral angiography within 7 days of admission regardless of the presence of manifest neurological insults. Patients were examined on a 64-MDCT Toshiba Aquilion scanner (Toshiba Medical Systems Europe B.V. Zoetermeer, The Netherlands) using the protocol: collimation, 0.75 mm; rotation time, 0.5 sec; table feed per rotation, 15 mm (pitch, 1.25); and reconstruction parameters 0.75 mm with an interval of 0.4 mm. Scanning was performed from the foramen magnum continuing upward to the centrum ovale. Injection of 90 mL of non-ionic contrast material was started before scanning at a flow rate of 3.5 mL/sec. Bolus tracking was performed with a region of interest placed in the extracranial portion of the internal carotid artery (10-sec monitoring delay). Other parameters were 120 kV, 100 mAs, 512 × 512 pixels, and a field of view of 200 mm. To construct 3D displays, we transferred the images to an independent imaging workstation. Patients with chronic kidney disease were scheduled for cerebral magnetic resonance angiography (MRA) without contrast. All examinations were reviewed and discussed by two neuroradiologists who assessed the presence, number, location and size of aneurysms as well as the associated findings, e.g., vasospasm and occlusions. We diagnosed aneurysms as mycotic in the setting of definite IE and with one of the following criteria:[11]

- The presence of another intra- or extracranial mycotic aneurysm.
- Rupture of the aneurysm.
- Arterial occlusion or stenosis adjacent to the aneurysm.
- Cerebral infarction due to arterial occlusion at the level of the aneurysm.

Patients were referred for cardiac surgery, when indicated, according to the American Heart Association guidelines.[12] We planned to refer patients with ICMA for invasive treatment if they had one of the following:

- ICMA diameter ≥ 7 mm.
- ICMA diameter ≥ 5 mm and amenable to endovascular treatment.
- Evidence of leakage around the ICMA.
- Location of the ICMA in the same territory as a symptomatic cerebral infarction.
- Increase in ICMA size on subsequent follow-up studies.

Patients with ICMA <5 mm were scheduled for follow-up angiography after two weeks. If the ICMA regressed or remained stable, then the patient was managed conservatively. When cardiac surgery was performed in patients with ICMA, it had to be either valve repair or replacement by a biological valve. We also decided to withhold oral anticoagulation in patients with ICMA till ICMA is managed or got thrombosed. We also deferred non-emergency cardiac surgery for 2 weeks in patients with ICMA even if asymptomatic and in patients with cerebral hemorrhage or large cerebral infarcts even if asymptomatic. We excluded patients who refused to sign the informed consent and patients who could not be referred for angiography within the first week of admission because of logistical reasons.

Statistical analysis

Numerical variables are described as the mean \pm standard deviation. Categorical variables are expressed as percentages. We measured the number of patients in whom we changed the treatment decisions based on the angiography findings as a percentage of the total cohort. Analysis

of the data collected was carried out by the Statistical Package for Social Sciences version 17 (SPSS 17.0) program.

Results

From July 2007 to December 2012, 150 patients were referred to the IE working group in Kasr El-Ainy teaching hospitals. Of them 102 consecutive patients had definite left sided IE. Only 81 consecutive patients underwent cerebral CTA/MRA within the first 1 week of admission. CTA was not performed in 21 patients for the following reasons: early death before CTA was performed ($n = 7$), refusal to participate ($n = 12$) or other logistical problems ($n = 2$). Eighty-one patients underwent cerebral angiography within 7 days of admission: 80 had CTA and 1 patient, with chronic kidney disease, had MRA without contrast. The mean age was 30.43 ± 8.8 years and 60.5% were males. The time from symptom onset until referral was relatively long. Staph aureus was the most common organism. The most common underlying valve pathology was rheumatic heart disease (Table 1). Symptomatic neurologic complications occurred in 34

Table 1. Clinical features.

Variable	N (%)
Time from symptom onset until presentation (days)	52.6±56.4
Underlying pathology	
Rheumatic	30 (37)
Prosthetic valve	21 (26)
Normal heart	19 (23.5)
Congenital heart disease	7 (8.6)
Degenerative valve disease	4 (5)
Mitral valve	46 (56.8)
Aortic valve	19 (23.5)
Both valves	13 (16)
VSD, PDA, Ao root	3 (3.7)
Healthcare-associated endocarditis*	25 (30.9)
Organisms	
Staph	20 (24.7)
Fungal	8 (10)
Strept	14 (17.3)
Brucella	8 (10)
Culture/serology negative	15 (18.5)
Other	24 (29.6)
Clinically symptomatic neurological complications	34 (42)
Any Major complication**	63 (77.8)
Sepsis requiring ventilation or vasopressor	23 (28.4)
Systemic embolization other than CNS	49 (60.5)
Heart failure	40 (49.4)
Death	15(18.5)

*defined as, 1. Nosocomial infection: infection contracted ≥ 48 hours after hospital admission. 2. Non nosocomial infection: infection appearing ≤ 48 hours of hospital admission within: a) 1 month of receiving IV cannulation, chemotherapy or dialysis; b) 3 months of admission into an acute care facility, c) any time of admission to a nursing home.

**sepsis, major artery embolization, heart failure, death.

doi:10.1371/journal.pone.0118616.t001

patients. ICMA occurred in 26 (32%) patients; of them 15 (18.5%) had no neurological manifestations. One patient had a silent brain infarction and another patient had a silent cerebral hemorrhage ([Table 2](#)). The angiography findings ([Fig. 1](#)) changed the treatment plan in 21 patients (25.6%); eleven of whom were neurologically asymptomatic. In 11 patients, more than one change of the treatment plan was made. These changes were:

- We referred 15 patients for invasive treatment of their ICMA based on the indications previously mentioned; of them 53.3% were asymptomatic. Thirteen patients (15.9%) were referred for endovascular treatment, of them six patients were neurologically asymptomatic. None of them developed procedure-related complications. Two patients were referred for surgical treatment of ICMA that were not amenable to endovascular treatment; both were neurologically silent. Neither had any procedure-related complications.
- Anticoagulation was stopped in 3 patients with prosthetic valve IE due to the presence of ICMA, 2 of them were silent.
- In 17 patients we had to change the type of cardiac surgery from mechanical valve replacement to repair or biological valve replacement as they had ICMA or asymptomatic hemorrhage. Eight of them had no neurological manifestations.

Among the 26 patients with ICMA, 21 (81%) had their management strategy modified on the basis of ICMA presence. This ratio was 73% in those with silent ICMA (11 out of 15 cases) where the detection of their asymptomatic ICMA led to treatment plan modifications. In general, treatment plan modifications were in accordance with the AHA/ACCF recommendations for the treatment and management of IE patients and the AHA recommendations for management of unruptured ICMA.[\[12–14\]](#)

[Fig. 2](#) shows the CTA results of a clinically silent ICMA together with its endovascular occlusion.

On follow-up CTA, one patient with multiple ICMA showed regression in the size of 3 aneurysms and thrombosis of another one; for this patient it was not feasible to perform neurosurgery or endovascular treatment. In another patient a small ICMA 4 mm in diameter showed complete regression. One patient showed thrombosis of a relatively large ICMA of 5.5 mm.


There was no major clinical or laboratory differences between patients in whom treatment plan was modified and others ([Table 3](#)).

Table 2. CT/CTA findings.

CT/CTA findings		95% confidence interval
Normal	30 (37)	
Silent infarction	1 (1.2)	26.49% to 47.51%
Manifest infarction	17 (21)	-1.17% to 3.57%
Silent cerebral hemorrhage*	2 (2.5)	12.13% to 29.87%
Manifest cerebral hemorrhage	20 (24.7)	-0.9% to 5.9%
ICMA	26 (32)	15.31% to 34.09%
Silent ICMA	15 (18.5)	21.84% to 42.16%
ICMA ≥ 5 mm	7 (8.6)	10.04% to 26.96%
ICMA ≥ 7 mm	19 (23.5)	2.49% to 14.71%

*one patient had a silent cerebral hemorrhage associated with silent ICMA.

doi:10.1371/journal.pone.0118616.t002

**Fig 1. Angiography findings of the studied patients.**

doi:10.1371/journal.pone.0118616.g001

Discussion

Our findings suggest that a significant proportion of left-sided IE patients have silent brain embolization that may dismally affect their outcome. Previous studies have been inconsistent regarding the incidence of brain embolization in IE and did not use vascular imaging systematically. Thuny et al.[15] utilized cerebral and thoraco-abdominal CT that revealed silent emboli in only 8% of patients. Cooper et al performed brain MRI in 40 patients with IE and found acute brain embolization in 80% of patients.[7] Lung et al. performed routine cerebral MRI and detected ischemic lesions in patients 53.3% of their 64 patients.[16] Lung et al also performed routine abdominal and cerebral parenchymal MRI in 58 patients with suspected IE within 7 days following admission. They modified therapeutic plans in 19% of their patients based solely on cerebral MRI, including surgical plan modification in 10% of patients.[17]

Over the past years, we have encountered catastrophic events due to neurological complications in general and ICMA in particular. Patients without manifest neurological disease can present fatal cerebral hemorrhage weeks after uneventful cardiac surgery and bacteriological

**Fig 2. CTA showing a small 3.5 mm ICMA of the right MCA.**

doi:10.1371/journal.pone.0118616.g002

Table 3. Clinical and laboratory characteristics of patients in whom CTA changed the treatment plan.

	CTA effect on decision		
	Did not affect decision	Affected decision	
Duration of symptoms before referral (days)	53.8±8	51.4±10	
organism identified	unknown	17	4
	staph aureus	11	6
	strept viridans	7	6
	eneterococci	2	1
	Brucella	7	1
	Bartonella	2	0
	Candida albicans	2	0
	aspergillus	4	1
Vegetations site	others	8	4
	mitral	38	10
	mitral & aortic	8	3
heart failure	aortic	11	8
	no severe HF	33	8
Major complications	severe HF	27	13
	non-complicated	10	0
	complicated	50	21
Total	60	21	

doi:10.1371/journal.pone.0118616.t003

cure. We also encountered several patients who bled intracranially waiting for elective cardiac surgery while apparently responding to antimicrobial therapy. Therefore, we decided to perform systematic screening for neurological complications in our referred patients.

To our knowledge this is the first study assessing the routine use of CTA for brain embolization detection in patients with left-sided IE and its impact on treatment plans. ICMA were the most common clinically silent brain embolization (32.1%). Most of the published data indicate much lower incidence (2–10%).[18,19] We believe that ICMA incidence is underestimated in the literature because no attempts were made to detect silent ICMA in asymptomatic patients—almost one third of the ICMA cases in this series.

Our findings might have been biased by tertiary center peculiarities that include: long interval from symptom onset to referral, more virulent organisms, high incidence of complications and frequent need for cardiac surgery. Applying a strategy of routine cerebral angiography screening in community settings may reveal different findings. In this study population patients characteristics are different from those of western IE patients [20,21]; however, they are more or less similar to those in publications from the Middle East and some developing countries.[22–25]

Although there are some significant differences from some of the recently published reports on IE [20,21], such as patients being significantly younger and RHD prevails, there are no significant differences from the MRA results reported by Duval et al. In that study routine MRA revealed at least 1 cerebral abnormality in 106 (82%) patients, sixteen of whom had neurologic symptoms. Nineteen (79%) of 114 patients without neurologic symptoms had cerebral abnormalities in MRA. The main difference in these findings is that Duval et al documented a lower incidence of unruptured ICMA.

Many published studies refer to the comparably high sensitivity and specificity of both CTA and MRA; however, CTA is much less expensive, easier to perform and much more suitable for critically ill patients.[26–30]

CT angiography is, at least, as accurate as magnetic resonance in diagnosis of intracranial aneurysms. In a study by Goto M et al, the accuracy of CT was similar to that of magnetic resonance in depicting branch vessels arising from the aneurysm sac in the middle cerebral artery. [31] In patients with a negative initial catheter angiogram computed tomography angiography had a higher yield than magnetic resonance demonstrating a causative cerebral aneurysm in 9.3% of patients.[32] Magnetic resonance angiography is more susceptible to artifacts and thus re-formatted surface-shaded volume-rendered 3-dimensional images of aneurysms from MRA might be inferior compared to those from CTA.[33]

MRA might be more sensitive for small embolic events but these won't have an impact on treatment plan in patients with definite/or possible IE.

In this study, mortality in ICMA patients (19%) was significantly lower than in most of the published data, which show rates approaching 60%. [34,35]. We assume that this might be related to the early detection and treatment of these ICMA before disastrous rupture occurs. The AHA guidelines on indications for neurovascular intervention provide some support to the practice of treating intracranial aneurysms before rupture if they are amenable to endovascular treatment.[14]

Conclusion

Routine assessment of aortic/mitral IE patients by cerebral angiography can change the treatment plan in a significant proportion of patients referred to tertiary care. This screening method is safe and may potentially improve the outcome of IE patients. We recommend future studies to compare a strategy of routine angiography versus standard care.

Author Contributions

Conceived and designed the experiments: MSM. Performed the experiments: AS. Analyzed the data: AS YB. Wrote the paper: MSM HHK. Performed radiologic interventions when needed: AZ. Supervised the work: HHR.

References

1. Habib G, Hoen B, Tornos P, Thuny F, Prendergast B, Vilacosta I, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009). European Heart Journal. 2009; p. 2369–413.
2. Heiro M, Nikoskelainen J, Engblom E, Kotilainen E, Marttila R, Kotilainen P. Neurologic manifestations of infective endocarditis: a 17-year experience in a teaching hospital in Finland. Arch Intern Med. 2000; 160:2781–7. PMID: [11025788](#)
3. Kassem HH, Hassan A, Gaber MRH. Clinical and Echocardiographic Predictors of In-Hospital Mortality in Patients with Infective Endocarditis. Hear J. 2012; 6:213–20.
4. Camarata PJ, Latchaw RE, Rüfenacht DA, Heros RCM. Intracranial Aneurysms. Invest Radiol. 1993; 28(4):373–82. PMID: [8478178](#)
5. Lerner PI. Neurologic complications of infective endocarditis. Med Clin North Am. 1985 Mar 1; 69 (2):385–98. PMID: [3838785](#)
6. Patel FM, Das A, Banerjee AK. Neuropathological complications of infective endocarditis: study of autopsy material. Neurol India. 2001 Mar 1; 49(1):41–6. PMID: [11303240](#)
7. Cooper HA, Thompson EC, Laureno R, Fuisz A, Mark AS, Lin M, et al. Subclinical brain embolization in left-sided infective endocarditis: results from the evaluation by MRI of the brains of patients with left-sided intracardiac solid masses (EMBOLISM) pilot study. Circulation. 2009 Aug 18; 120(7):585–91. doi: [10.1161/CIRCULATIONAHA.108.834432](#) PMID: [19652096](#)

8. Thuny F, Avierinos J-F, Tribouilloy C, Giorgi R, Casalta J-P, Milandre L, et al. Impact of cerebrovascular complications on mortality and neurologic outcome during infective endocarditis: a prospective multi-centre study. *Eur Heart J.* 2007 May 1; 28(9):1155–61. PMID: [17363448](#)
9. Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG, Ryan T, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. *Clin Infect Dis.* 2000 Apr 1; 30(4):633–8. PMID: [10770721](#)
10. Easton JD, Saver JL, Albers GW, Alberts MJ, Chaturvedi S, Feldmann E, et al. Definition and evaluation of transient ischemic attack: A scientific statement for healthcare professionals from the American heart association/American stroke association stroke council; council on cardiovascular surgery and anesthesia; council on cardio. *Stroke.* 2009. p. 2276–93.
11. Chapot R, Houdart E, Saint-Maurice J-P, Aymard A, Mounayer C, Lot G, et al. Endovascular treatment of cerebral mycotic aneurysms. *Radiology.* Radiological Society of North America; 2002 Feb 1; 222(2):389–96.
12. Baddour LM, Wilson WR, Bayer AS, Fowler VG, Bolger AF, Levison ME, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young,. *Circulation.* 2005.
13. Bederson JB, Awad IA, Wiebers DO, Piepgras D, Haley EC, Brott T, et al. Recommendations for the management of patients with unruptured intracranial aneurysms: A statement for healthcare professionals from the Stroke Council of the American Heart Association. *Circulation.* 2000; 102:2300–8. PMID: [11056108](#)
14. Meyers PM, Schumacher HC, Higashida RT, Barnwell SL, Creager MA, Gupta R, et al. Indications for the performance of intracranial endovascular neurointerventional procedures: A scientific statement from the American Heart Association Council on Cardiovascular Radiology and Intervention, Stroke Council, Council on Cardiovascular Surgery. *Circulation.* 2009. p. 2235–9.
15. Thuny F, Disalvo G, Belliard O, Avierinos JF, Pergola V, Rosenberg V, et al. Risk of embolism and death in infective endocarditis: Prognostic value of echocardiography—A prospective multicenter study. *Circulation.* 2005; 112:69–75. PMID: [15983252](#)
16. Iung B, Tubiana S, Klein I, Messika-Zeitoun D, Brochet E, Lepage L, et al. Determinants of cerebral lesions in endocarditis on systematic Cerebral magnetic resonance imaging: A prospective study. *Stroke.* 2013; 44:3056–62. doi: [10.1161/STROKEAHA.113.001470](#) PMID: [24003046](#)
17. Iung B, Klein I, Mourvillier B, Olivot J-M, Détaint D, Longuet P, et al. Respective effects of early cerebral and abdominal magnetic resonance imaging on clinical decisions in infective endocarditis. *Eur Heart J Cardiovasc Imaging.* 2012; 13:703–10. doi: [10.1093/eihci/jes023](#) PMID: [22334638](#)
18. Hoen B, Alla F, Selton-Suty C, Béguinot I, Bouvet A, Briançon S, et al. Changing profile of infective endocarditis: results of a 1-year survey in France. *JAMA.* 2002; 288:75–81. PMID: [12090865](#)
19. Tleyjeh IM, Steckelberg JM, Murad HS, Anavekar NS, Ghomrawi HMK, Mirzoyev Z, et al. Temporal trends in infective endocarditis: a population-based study in Olmsted County, Minnesota. *JAMA.* 2005; 293:3022–8. PMID: [15972564](#)
20. Hoen B, Duval X. Infective Endocarditis. *N Engl J Med.* 2013; 368:1425–33. doi: [10.1056/NEJMcp1206782](#) PMID: [23574121](#)
21. Duval X, Iung B, Klein I, Brochet E, Thabut G, Arnoult F, et al. Effect of early cerebral magnetic resonance imaging on clinical decisions in infective endocarditis: A prospective study. *Ann Intern Med.* 2010; 152:497–504. doi: [10.7326/0003-4819-152-8-201004200-00006](#) PMID: [20404380](#)
22. Tuğcu A, Yıldırımtürk Ö, Baytaroğlu C, Kurtoğlu H, Köse Ö, Şener M, et al. Clinical spectrum, presentation, and risk factors for mortality in infective endocarditis: a review of 68 cases at a tertiary care center in Turkey. *Turk Kardiyol Dern Ars.* 2009; 37(1):9–18. PMID: [19225248](#)
23. Garg N, Kandpal B, Garg N, Tewari S, Kapoor A, Goel P, et al. Characteristics of infective endocarditis in a developing country-clinical profile and outcome in 192 Indian patients, 1992–2001. *Int J Cardiol.* 2005; 98:253–60. PMID: [15686775](#)
24. Trabelsi I, Rekik S, Znazen A, Maaloul I, Abid D, Maalej A, et al. Native Valve Infective Endocarditis in a Tertiary Care Center in a Developing Country (Tunisia). *Am J Cardiol.* 2008; 102:1247–51. doi: [10.1016/j.amjcard.2008.06.052](#) PMID: [18940301](#)
25. Nunes MCP, Gelape CL, Ferrari TCA. Profile of infective endocarditis at a tertiary care center in Brazil during a seven-year period: Prognostic factors and in-hospital outcome. *Int J Infect Dis.* 2010; 14.
26. Piotin M, Gailloud P, Bidaut L, Mandai S, Muster M, Moret J, et al. CT angiography, MR angiography and rotational digital subtraction angiography for volumetric assessment of intracranial aneurysms. An experimental study. *Neuroradiology.* 2003; 45:404–9. PMID: [12719951](#)

27. Hiratsuka Y, Miki H, Kiriyma I, Kikuchi K, Takahashi S, Matsubara I, et al. Diagnosis of unruptured intracranial aneurysms: 3T MR angiography versus 64-channel multi-detector row CT angiography. *Magn Reson Med Sci.* 2008; 7:169–78. PMID: [19110511](#)
28. Karamessini MT, Kagadis GC, Petsas T, Karnabatidis D, Konstantinou D, Sakellaropoulos GC, et al. CT angiography with three-dimensional techniques for the early diagnosis of intracranial aneurysms. Comparison with intra-arterial DSA and the surgical findings. *Eur J Radiol.* 2004; 49:212–23. PMID: [14962650](#)
29. Uysal E, Yanbuloğlu B, Ertürk M, Kilinç BM, Başak M. Spiral CT angiography in diagnosis of cerebral aneurysms of cases with acute subarachnoid hemorrhage. *Diagn Interv Radiol.* 2005; 11:77–82. PMID: [15957092](#)
30. White PM, Teasdale EM, Wardlaw JM, Easton V. Intracranial aneurysms: CT angiography and MR angiography for detection prospective blinded comparison in a large patient cohort. *Radiology.* 2001 p. 739–49.
31. Goto M, Kunimatsu A, Shojima M, Mori H, Abe O, Aoki S, et al. Depiction of branch vessels arising from intracranial aneurysm sacs: Time-of-flight MR angiography versus CT angiography. *Clin Neurol Neurosurg.* Elsevier; 2014 Nov 11; 126:177–84. doi: [10.1016/j.clineuro.2014.09.003](#) PMID: [25270230](#)
32. Delgado Almandoz JE, Jagadeesan BD, Refai D, Moran CJ, Cross DT, Chicoine MR, et al. Diagnostic yield of computed tomography angiography and magnetic resonance angiography in patients with catheter angiography–negative subarachnoid hemorrhage. *Journal of Neurosurgery.* 2012. p. 309–15.
33. Numminen J, Tarkainen A, Niemelä M, Porras M, Hernesniemi J, Kangasniemi M. Detection of unruptured cerebral artery aneurysms by MRA at 3.0 tesla: comparison with multislice helical computed tomographic angiography. *Acta radiol.* 2011; 52:670–4. doi: [10.1258/ar.2011.100421](#) PMID: [21525105](#)
34. Wajnberg E, Rueda F, Marchiori E, Gasparetto EL. Endovascular treatment for intracranial infectious aneurysms. *Arq Neuropsiquiatr.* 2008; 66:790–4. PMID: [19099112](#)
35. Erdogan HB, Erentug V, Bozbuga N, Goksedef D, Akinci E, Yakut C. Endovascular treatment of intracerebral mycotic aneurysm before surgical treatment of infective endocarditis. *Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital.* 2004. p. 165–7.